Audiologic Follow‐up in Patients With Head and Neck Cancer Treated With Cisplatin and Radiation

Abstract

ObjectivesEvaluate factors associated with adherence to ototoxicity monitoring among patients with head and neck cancer treated with cisplatin and radiation therapy at a tertiary care center.MethodsWe performed a single‐institution retrospective cohort study on adults with head and neck cancer treated with cisplatin and radiation therapy who participated in an ototoxicity monitoring program. The primary outcomes were rates of post‐treatment audiograms at the following time points: one, three, six, 12, and greater than 12 months. Multivariable logistic regression was performed to identify risk factors associated with complete loss of follow‐up after pre‐treatment evaluation.ResultsTwo hundred ninety‐four head and neck cancer patients were analyzed. Overall, 220 (74.8%) patients had at least one post‐treatment audiogram; 58 (20.0%) patients had more than one audiogram. The time point with the highest follow‐up rate was at 3 months (n = 170, 57.8%); rates at the remaining times ranged from 7.1% to 14.3%. When controlling for covariates, patients without insurance and those with stage IV cancers were associated with complete loss of audiologic follow‐up (aOR = 7.18, 95% CI = 2.75–19.90; aOR = 1.96, 95% CI = 1.02–3.77, respectively). Among 156 patients recommended for a hearing aid, only 39 (24.8%) patients received one.ConclusionsHead and neck cancer patients enrolled in an ototoxicity monitoring program demonstrate moderately high follow‐up rates for at least one post‐treatment audiogram. However, follow‐up tapers dramatically after 6 months, and overall hearing aid utilization is low. Further research is needed to understand barriers to long‐term audiologic follow‐up and hearing aid utilization to decrease untreated hearing loss in cancer survivorship.Level of EvidenceLevel 3 Laryngoscope, 133:3161–3168, 2023